Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 16/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29263913 | 0.91 | CASP1 (0.41) | CASP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10887551 | 0.90 | SMN1; SMN2 (0.45) | CASP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL16289607 | 0.90 | SMN1; SMN2 (0.46) | CASP1SMN1; SMN2ALDH1A1ITGB1ITGA4 | |
| SCHEMBL16289609 | 0.90 | SMN1; SMN2 (0.46) | CASP1SMN1; SMN2ALDH1A1ITGB1ITGA4 | |
| SCHEMBL13116156 | 0.86 | SMN1; SMN2 (0.43) | CASP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10980192 | 0.85 | CASP1 (0.40) | CASP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21978267 | 0.84 | CASP1 (0.47) | CASP1ALDH1A1 | |
| SCHEMBL21978269 | 0.84 | CASP1 (0.47) | CASP1ALDH1A1 | |
| SCHEMBL10885200 | 0.84 | CASP1 (0.47) | CASP1ALDH1A1 | |
| SCHEMBL10986526 | 0.83 | FOLH1 (0.53) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937334-B1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | PROMENTIS PHARM INC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2937334-A1 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8815905-B2 | Propionic acids, propionic acid esters, and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2545033-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112535-A2 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | ALBANY MOLECULAR RESEARCH, INC. | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224156-A1 | Propionic Acids, Propionic Acid Esters, and Related Compounds | PCCA, PC, PMP22 | CASP1 2461/4885SMN1; SMN2 144/4885ALDH1A1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.